JP2020504131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504131A5 JP2020504131A5 JP2019536488A JP2019536488A JP2020504131A5 JP 2020504131 A5 JP2020504131 A5 JP 2020504131A5 JP 2019536488 A JP2019536488 A JP 2019536488A JP 2019536488 A JP2019536488 A JP 2019536488A JP 2020504131 A5 JP2020504131 A5 JP 2020504131A5
- Authority
- JP
- Japan
- Prior art keywords
- galactosidase
- recombinant human
- weeks
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022192939A JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442537P | 2017-01-05 | 2017-01-05 | |
| US62/442,537 | 2017-01-05 | ||
| PCT/IL2018/050018 WO2018127920A1 (en) | 2017-01-05 | 2018-01-05 | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192939A Division JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504131A JP2020504131A (ja) | 2020-02-06 |
| JP2020504131A5 true JP2020504131A5 (https=) | 2021-02-12 |
Family
ID=62790830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536488A Pending JP2020504131A (ja) | 2017-01-05 | 2018-01-05 | 安定化α−ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
| JP2022192939A Pending JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192939A Pending JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12194079B2 (https=) |
| EP (1) | EP3565583A4 (https=) |
| JP (2) | JP2020504131A (https=) |
| KR (2) | KR20240042110A (https=) |
| CN (2) | CN117959455A (https=) |
| AU (1) | AU2018205891B2 (https=) |
| BR (1) | BR112019013920A2 (https=) |
| CA (1) | CA3048151A1 (https=) |
| CL (1) | CL2019001867A1 (https=) |
| IL (1) | IL267863A (https=) |
| MX (1) | MX2019008076A (https=) |
| NZ (1) | NZ755725A (https=) |
| WO (1) | WO2018127920A1 (https=) |
| ZA (1) | ZA201904850B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| MX2021015352A (es) * | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| US20230416714A1 (en) * | 2020-11-13 | 2023-12-28 | Hanmi Pharm. Co., Ltd | Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by fabry disease |
| AU2021378707A1 (en) * | 2020-11-13 | 2023-06-01 | Hanmi Pharm. Co., Ltd. | Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by Fabry disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| DK1503788T3 (da) * | 2002-04-25 | 2011-10-17 | Shire Human Genetic Therapies | Behandling af alpha-galactosidase A-deficiens |
| EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| CA2696699A1 (en) | 2007-08-20 | 2009-02-26 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| US9194011B2 (en) * | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| US20120230974A1 (en) | 2009-11-17 | 2012-09-13 | Protalix Ltd | Alkaline alpha galactosidase for the treatment of fabry disease |
| SI2865751T1 (sl) | 2010-03-02 | 2017-01-31 | Protalix Ltd. | Stabilizirana alfa-galaktozidaza in njene uporabe |
| KR101883803B1 (ko) | 2011-01-20 | 2018-07-31 | 프로탈릭스 리미티드 | 식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물 |
| WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
-
2018
- 2018-01-05 WO PCT/IL2018/050018 patent/WO2018127920A1/en not_active Ceased
- 2018-01-05 US US16/476,084 patent/US12194079B2/en active Active
- 2018-01-05 NZ NZ755725A patent/NZ755725A/en unknown
- 2018-01-05 MX MX2019008076A patent/MX2019008076A/es unknown
- 2018-01-05 EP EP18736643.0A patent/EP3565583A4/en active Pending
- 2018-01-05 KR KR1020247008410A patent/KR20240042110A/ko not_active Ceased
- 2018-01-05 AU AU2018205891A patent/AU2018205891B2/en active Active
- 2018-01-05 BR BR112019013920A patent/BR112019013920A2/pt unknown
- 2018-01-05 CA CA3048151A patent/CA3048151A1/en active Pending
- 2018-01-05 CN CN202410140178.XA patent/CN117959455A/zh active Pending
- 2018-01-05 CN CN201880016068.5A patent/CN110381987A/zh active Pending
- 2018-01-05 JP JP2019536488A patent/JP2020504131A/ja active Pending
- 2018-01-05 KR KR1020197023039A patent/KR20190103320A/ko not_active Ceased
-
2019
- 2019-07-04 CL CL2019001867A patent/CL2019001867A1/es unknown
- 2019-07-04 IL IL267863A patent/IL267863A/en unknown
- 2019-07-24 ZA ZA2019/04850A patent/ZA201904850B/en unknown
-
2022
- 2022-12-01 JP JP2022192939A patent/JP2023022244A/ja active Pending
-
2025
- 2025-01-10 US US19/015,746 patent/US20250134968A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504131A5 (https=) | ||
| JP2020007350A5 (https=) | ||
| JP2017527532A5 (https=) | ||
| JP2014500295A5 (https=) | ||
| CN101111154A (zh) | 联合免疫基因疗法和化学疗法用于治疗癌症和过度增生性疾病 | |
| JP2021505661A5 (https=) | ||
| JP2012526850A5 (https=) | ||
| CA2522535A1 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
| JP2012525393A5 (https=) | ||
| US20100266590A1 (en) | Combination therapy | |
| JP2019131588A5 (ja) | 抗そう痒剤 | |
| JP2010511596A5 (https=) | ||
| JP2022502432A5 (https=) | ||
| JP2007520452A5 (https=) | ||
| EP1201247B1 (en) | Treatment of metastatic renal cell carcinoma | |
| JP2019524637A (ja) | 抗腫瘍薬物の効果を有する併用薬物 | |
| JP2021001184A (ja) | ペグ化インターフェロンのための投薬計画 | |
| JP2005512946A5 (https=) | ||
| JP2021535163A5 (https=) | ||
| JP2020531495A5 (https=) | ||
| WO2023272831A1 (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| CN104434908A (zh) | 山奈酚在抑制受体对器官移植排斥反应药物中的应用 | |
| JP3022915B2 (ja) | 癌転移抑制剤 | |
| US12053478B2 (en) | Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies | |
| JP6112009B2 (ja) | 体腔液貯留抑制剤 |